Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study

Fig. 3

Value of C3 in predicting VSP treated with tocilizumab in patients with TA. A ROC curves of C3 for identifying VSP in 1 year (cut-off level: 1.22 g/L). B Kaplan-Meir curves of VSP with respect to different C3 levels. C ROC curves of C3 for identifying VISE in 1 year (cut-off level: 1.0 g/L). D Kaplan-Meir curves of VISE with respect to different C3 levels. C3, complement 3; ROC, receiving operating characteristic; VSP, vascular stenosis progression; VISE, vascular ischemic symptoms and events

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us